Cambium Bio Secures $2.4M at 20% Premium to Fund Phase 3 Eye Disease Trial

Cambium Bio has secured a $2.4 million strategic investment from major shareholder Zheng Yang Biomedical Technology Co., Ltd. (ZYBT), with shares priced at $0.55 each. This represents a 20% premium to the company’s closing price of $0.46 on 19 January 2026. The placement will see ZYBT’s stake increase from 28.1% to 39.6%, subject to shareholder approval at a General Meeting scheduled for 16 March 2026. Funds will be directed toward initiating patient dosing in pivotal Phase 3 clinical trials for Elate Ocular® across the United States, Australia, and Taiwan, targeted for Q2 2026.

Why Did ZYBT Invest in Cambium Bio at a 20% Premium?

The 20% premium pricing signals strong conviction from an investor with unique insight into Cambium Bio’s clinical and commercial prospects. ZYBT has been a strategic partner since 2014, when the parties entered into a joint development agreement for products incorporating fibrinogen-depleted human platelet lysate technology. ZYBT currently holds worldwide manufacturing rights for the Active Biologic Ingredient and commercialisation rights for Elate Ocular® in China, Singapore, and Taiwan.

This dual role as both manufacturer and commercialisation partner positions ZYBT with direct exposure to Elate Ocular’s success. The premium reflects their assessment of the therapy’s potential within the US$6 billion global dry eye disease market, where successful Phase 3 execution could support regulatory approval and commercial launch.

“We are pleased to receive this strong show of support from ZYBT, our largest shareholder and long-term strategic partner. Their willingness to invest at a significant premium to the current trading price reflects their deep understanding of the clinical and commercial opportunity for Elate Ocular® in the US$6 billion dry eye disease market,” said Karolis Rosickas, Chief Executive Officer.

The premium pricing provides a reference point for investors evaluating the company’s market valuation ahead of critical Phase 3 milestones.

Understanding Dry Eye Disease: The Market Opportunity

Dry eye disease is a chronic condition where the eyes do not produce enough tears or the tears evaporate too quickly, resulting in discomfort, visual disturbance, and potential damage to the eye surface. It affects millions globally and significantly impacts quality of life, particularly among ageing populations and individuals with extended screen exposure.

Current treatment options are largely limited to artificial tears and anti-inflammatory medications, which address symptoms but may not resolve underlying causes. Elate Ocular® employs a biologic approach using human platelet lysate technology, which aims to support natural healing processes at the ocular surface.

The US$6 billion market size reflects substantial commercial opportunity, driven by high prevalence rates and limited therapeutic alternatives. For investors, this large addressable market creates potential for meaningful revenue generation if Phase 3 trials demonstrate efficacy and safety sufficient for regulatory approval. The funding secured through this placement directly enables Cambium Bio to advance toward market entry through completion of pivotal clinical studies.

How Will Cambium Bio Use the $2.4 Million Funding?

The $2.4 million raised via the placement will be allocated across three specific use categories:

1. Initiate patient dosing in pivotal Phase 3 clinical trials for Elate Ocular® across the United States, Australia, and Taiwan.
2. Complete manufacture of investigational drug product required for Phase 3 trials.
3. Provide working capital for the company’s ongoing operations.

This capital allocation directly supports value-creating milestones on the pathway to commercialisation. Patient dosing in Phase 3 represents the final clinical hurdle before potential regulatory submission, with topline data expected in H2 2027. Manufacturing completion ensures the investigational product meets regulatory standards for multi-site clinical deployment.

The company has supplemented this funding with additional sources, including a $0.6 million R&D Tax Incentive refund received in December 2025. Management has indicated that together with non-dilutive funding options and potential other financing initiatives, the board believes Cambium Bio is positioned to launch the pivotal Phase 3 programme across all three target geographies.

The Q2 2026 dosing target establishes a near-term catalyst, with the funding providing certainty around execution timelines.

What Does ZYBT’s Increased Stake Mean for Cambium Bio Shareholders?

ZYBT’s stake increase from 28.1% to 39.6% requires shareholder approval under ASX Listing Rules and the Corporations Act 2001, as ZYBT is considered a related party. Dr Sebastian Tseng, Chairman of ZYBT, serves as a Non-Executive Director of Cambium Bio, creating a governance requirement for independent shareholder assessment.

The company will convene a virtual General Meeting on 16 March 2026 to seek approval for the share issuance. An Independent Expert Report is being prepared to assist non-associated shareholders in evaluating the transaction’s merits. The board (with Dr Tseng abstaining) has reviewed and approved the placement terms, determining they are on arm’s length or better and in the best interests of all shareholders.

The 39.6% stake positions ZYBT as the controlling shareholder without triggering mandatory takeover obligations, as shareholder approval addresses section 611 requirements. For minority investors, the transparent governance process and independent expert assessment provide mechanisms to evaluate whether the placement terms are fair and reasonable. The strategic alignment between ZYBT’s manufacturing capabilities and commercialisation rights may support execution efficiency as the company advances toward regulatory milestones.

Phase 3 Pivotal Trial: The Path to Commercialisation

The Phase 3 clinical programme represents the final regulatory hurdle before potential market approval for Elate Ocular®. The company has achieved several de-risking milestones ahead of patient dosing:

• FDA alignment on clinical trial design and Chemistry, Manufacturing, and Controls (CMC) matters
• FDA Fast Track designation for Elate Ocular®
• Ethics committee and institutional review board approvals in place
• Multi-site activation underway across the United States, Australia, and Taiwan

Fast Track designation from the FDA is granted to therapies addressing serious conditions with potential to fill unmet medical needs. This status facilitates more frequent interactions with the FDA during development and may expedite the review process if clinical data support approval.

The company is actively working to manufacture the investigational drug product required to commence dosing patients in Q2 2026. Topline data are expected in H2 2027, establishing a clear timeline for the primary value inflection point. The three-country trial footprint distributes regulatory risk while supporting potential commercial pathways in multiple geographies where ZYBT holds varying commercialisation rights.

For investors, the funded pathway to pivotal data with regulatory validation already secured reduces execution uncertainty. The Q2 2026 dosing timeline provides a near-term catalyst, while the H2 2027 data readout represents the critical decision point for regulatory submission and commercial viability.

The Investment Thesis: Strategic Backing Meets Clinical Execution

The strategic investment strengthens Cambium Bio’s position through several mechanisms. The 20% premium pricing from an informed insider with manufacturing and commercialisation exposure provides a valuation reference point that contrasts with the company’s $0.46 market price before the announcement. This creates potential asymmetry for public market investors evaluating the opportunity before Phase 3 data becomes available.

ZYBT’s dual role as both manufacturing partner and commercial rights holder in key Asian markets aligns incentives and may de-risk supply chain execution as the therapy advances toward potential approval. The secured funding removes capital constraints as a near-term execution risk, enabling management to focus on clinical trial execution and regulatory interactions.

The investment thesis centres on multiple value inflection points over the next 18 months. Patient dosing in Q2 2026 provides confirmation of trial initiation, while topline data in H2 2027 will determine whether Elate Ocular® demonstrates efficacy and safety profiles sufficient for regulatory submission. The US$6 billion dry eye disease market opportunity creates substantial commercial runway if clinical execution succeeds.

For investors assessing materiality, the combination of premium pricing from a strategic insider, secured funding to pivotal data, and FDA Fast Track designation establishes a de-risked pathway relative to earlier-stage biotechnology investments. The shareholder approval process on 16 March 2026 provides a mechanism for minority investors to assess the transaction’s fairness through an Independent Expert Report before the placement completes.

Want More Biotech Breakthroughs Like This?

Cambium Bio’s premium-priced placement and upcoming Phase 3 trial represent exactly the type of development-stage catalyst that biotech-focused investors monitor. When companies secure strategic backing at premiums and advance toward pivotal data readouts, timing matters. Subscribers to the Big News Blast from StockWire X received this alert within hours of the announcement, with full context on the implications for valuation and execution risk. The service delivers breaking news across non-resource ASX sectors—including Biotech, Healthcare, Tech, and Finance—with comprehensive analysis trusted by over 20,000 active investors.

The next regulatory milestone or strategic partnership could emerge without warning. Click the “Free Alerts” button in the menu at StockWire X to receive immediate notifications on ASX biotech developments, clinical trial updates, and capital raising events that move share prices. The service is entirely free and focuses exclusively on sectors with catalysts driven by innovation rather than commodity cycles.